[{"address1": "19925 Stevens Creek Boulevard", "address2": "Suite 100", "city": "Cupertino", "state": "CA", "zip": "95014", "country": "United States", "phone": "408 501 8881", "fax": "408 904 6270", "website": "https://revivapharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention\u0096deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is based in Cupertino, California.", "fullTimeEmployees": 10, "companyOfficers": [{"maxAge": 1, "name": "Dr. Laxminarayan  Bhat Ph.D.", "age": 58, "title": "Founder, CEO, President & Director", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": 560000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Narayan  Prabhu", "age": 51, "title": "Chief Financial Officer", "yearBorn": 1972, "fiscalYear": 2022, "totalPay": 412500, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.89, "open": 3.9, "dayLow": 3.81, "dayHigh": 3.92, "regularMarketPreviousClose": 3.89, "regularMarketOpen": 3.9, "regularMarketDayLow": 3.81, "regularMarketDayHigh": 3.92, "beta": -0.014, "forwardPE": -3.3652174, "volume": 189911, "regularMarketVolume": 189911, "averageVolume": 1386771, "averageVolume10days": 272180, "averageDailyVolume10Day": 272180, "bid": 3.83, "ask": 3.93, "bidSize": 1000, "askSize": 1000, "marketCap": 108044976, "fiftyTwoWeekLow": 3.5, "fiftyTwoWeekHigh": 9.25, "fiftyDayAverage": 4.3198, "twoHundredDayAverage": 5.1079, "currency": "USD", "enterpriseValue": 82906728, "floatShares": 18599719, "sharesOutstanding": 27918600, "sharesShort": 732385, "sharesShortPriorMonth": 902346, "sharesShortPreviousMonthDate": 1702598400, "dateShortInterest": 1705017600, "sharesPercentSharesOut": 0.026199998, "heldPercentInsiders": 0.17768, "heldPercentInstitutions": 0.09555, "shortRatio": 1.15, "shortPercentOfFloat": 0.0319, "impliedSharesOutstanding": 27918600, "bookValue": -0.376, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -37654704, "trailingEps": -1.68, "forwardEps": -1.15, "52WeekChange": -0.10161662, "SandP52WeekChange": 0.21733451, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "RVPH", "underlyingSymbol": "RVPH", "shortName": "Reviva Pharmaceuticals Holdings", "longName": "Reviva Pharmaceuticals Holdings, Inc.", "firstTradeDateEpochUtc": 1539869400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "5d62d57c-1d1b-37f4-af52-0b59eba3195a", "messageBoardId": "finmb_126911636", "gmtOffSetMilliseconds": -18000000, "currentPrice": 3.87, "targetHighPrice": 20.0, "targetLowPrice": 12.0, "targetMeanPrice": 16.83, "targetMedianPrice": 17.5, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 4972298, "totalCashPerShare": 0.22, "totalDebt": 222500, "quickRatio": 0.382, "currentRatio": 0.413, "returnOnAssets": -1.58392, "returnOnEquity": -6.36055, "freeCashflow": -10570032, "operatingCashflow": -24138542, "financialCurrency": "USD", "trailingPegRatio": null}]